Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.40 |
| ▸ | HPGD | P15428 | 9/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.40 |
| ▸ | PKM | P14618 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.40 |
| ▸ | GLA | P06280 | 5/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 3/20 | 0.40 |
| ▸ | CASP7 | P55210 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763257 | 0.80 | ALDH1A1 (0.44) | ADORA2AADORA1ALDH1A1HPGDKDM4E | |
| SCHEMBL929213 | 0.80 | ALDH1A1 (0.44) | ADORA2AADORA1ALDH1A1HPGDKDM4E | |
| SCHEMBL2763137 | 0.78 | ALDH1A1 (0.45) | ADORA2AADORA1ALDH1A1HPGDKDM4E | |
| SCHEMBL930783 | 0.78 | KDM4E (0.49) | ADORA2AADORA1ALDH1A1HPGDKDM4E | |
| SCHEMBL2762872 | 0.77 | ADORA2A (0.59) | ADORA2AADORA1ALDH1A1HPGDKDM4E | |
| SCHEMBL2763990 | 0.75 | ADORA2A (0.46) | ADORA2AADORA1ALDH1A1HPGDKDM4E | |
| SCHEMBL2763076 | 0.74 | ALDH1A1 (0.42) | ADORA2AADORA1ALDH1A1HPGDKDM4E | |
| SCHEMBL13111256 | 0.72 | TDP1 (0.53) | ADORA1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL2762992 | 0.72 | ALDH1A1 (0.38) | ADORA2AADORA1ALDH1A1HPGDKDM4E | |
| SCHEMBL1318655 | 0.71 | POLB (0.42) | ADORA1ALDH1A1MAPTTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1720553-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R&D) LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ALDH1A1 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.